Biobob

Cypress Bioscience Could Be a Buy Given Upcoming FDA Decision

There has recently (6/11/08) been a Phase 3 study of 883 patients done by Pierre Fabre Medicament (France) evaluating Milnacipran for FM, using, I believe, the same measurement criteria as was/ is used by CYPB/FRX in their studies. These results were presented at the EULAR conference in Paris, France on 6/11/08. The results were as significant or more significant than the second Phase III test run by CYPB/FRX, with "significantly greater improvement" in the composite responder test (P>0.0003) and in the key secondary criterion, FIQ score (P>0.015). Reference below, or search <Pierre Fabre milnacipran>.

Pierre Fabre Medicament Announces Submission of a Market ...CASTRES, France, June 11, 2008 – Pierre Fabre Medicament today presented positive Phase III data from their milnacipran fibromyalgia (FM) study in adult ...
drugs.com/.../pierre-f...... - 33k - Cached - Similar pages